The vaccine demonstrated an excellent safety profile and 93.28% protective efficacy 14 days after injection. Credit: WestVac BioPharma Co., Ltd./ CNW.

WestVac Biopharma has announced that the Chinese authorities have granted emergency use authorisation (EUA) for coviccine trivalent XBB.1.5-recombinant Covid-19 trivalent (XBB.1.5+BA.5+delta) protein vaccine (Sf9 cell).

This marks the world’s first Covid-19 vaccine approved for emergency use against XBB descendent lineages of SARS-CoV-2.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The vaccine has been developed by WestVac Biopharma along with the West China Medical Center and Sichuan University.

WestVac Biopharma and its subsidiary WestVac Biopharma (Guangzhou) constructed the vector for the coviccine vaccine using the fast response of the insect cell expression platform.

The subunit antigen in the vaccine has been based on the structure of the targeting S-RBD and HR proteins of the XBB and BA.5 subvariants.

It is self-assembled into stable trimeric protein particles with the addition of squalene-based oil-in-water emulsion adjuvant following purification and mixing.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Trials demonstrated that the vaccine induced a high titer of neutralising antibodies against several subvariants, including Omicron subvariants XBB.1.5, XBB1.16, XBB1.9.1, XBB.2.3, BA.2.75, BQ.1, BA.5 and BF.7.

The vaccine demonstrated an excellent safety profile and 93.28% protective efficacy against XBB.1, XBB.1.5, and XBB1.9, 14 days after injection.

The results indicated that coviccine trivalent XBB.1.5 is a Covid-19 vaccine with a broad spectrum to tackle several prevalent subvariants in China and globally.

China’s authorities granted an EUA for WestVac Biopharma’s coviccine-recombinant Covid-19 vaccine (Sf9 cell) in December 2022.